NASDAQ
1.18USD
+0.04 (+3.46%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
75.1M
P/E
—
EPS
—
Beta
0.46
52W range
0.87-2.35
Day range
1.14–1.23
Open
1.15
Prev close
1.14
Volume
509.7K
Avg volume
424.9K
Dividend
0.00
IPO
2018-11-20
https://www.proactiveinvestors.com/companies/news/1097492 · 8/24/2026+0.40
https://www.proactiveinvestors.com/companies/news/1092705 · 5/21/2026+0.80
https://www.proactiveinvestors.com/companies/news/1085940 · 1/20/2026+0.80
https://www.globenewswire.com/news-release/2026/01/16/3220529/0/en/Tiziana-Life-Sciences-Announces-Closing-of-Oversubscribed-8-8-Million-Registered-Direct-Offering-of-Ordinary-Shares.html · 1/16/2026+0.60
https://www.globenewswire.com/news-release/2025/12/29/3210895/0/en/Tiziana-Files-Annual-Safety-Report-for-Intranasal-Foralumab-with-FDA.html · 12/29/2025+0.60
https://www.proactiveinvestors.com/companies/news/1084771/tiziana-life-sciences-begins-dosing-in-phase-2-alzheimer-s-trial-icymi-1084771.html · 12/20/2025+0.80
https://www.globenewswire.com/news-release/2025/12/17/3206982/0/en/Tiziana-Life-Sciences-Doses-First-Patient-in-Phase-2-Alzheimer-s-Clinical-Trial.html · 12/17/2025+0.60
https://www.proactiveinvestors.com/companies/news/1083170 · 11/25/2025+0.80
https://www.globenewswire.com/news-release/2025/09/30/3158596/0/en/Tiziana-Life-Sciences-Invited-to-Attend-Life-Sciences-Innovation-Forum-2025-in-Riyadh-Saudi-Arabia.html · 9/30/2025+0.60
https://www.proactiveinvestors.com/companies/news/1079192 · 9/25/2025+0.80
https://www.globenewswire.com/news-release/2025/09/24/3155461/0/en/Tiziana-Life-Sciences-Announces-Poster-Presentation-on-Intranasal-Foralumab-Clinical-Trial-at-the-41st-ECTRIMS-Congress.html · 9/24/2025+0.60
https://www.globenewswire.com/news-release/2025/09/05/3145254/0/en/Tiziana-Life-Sciences-Announces-Purchase-of-Shares-by-Chairman.html · 9/5/2025+0.60
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
